Skip to content
Gold Mining News – Lifestyle
Home
Sample Page
Author:
Cognition Therapeutics, Inc.
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
August 6, 2026
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities’ Mind, Muscle & Vision Summit
July 13, 2026
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
June 24, 2026
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
June 16, 2026
Cognition Therapeutics Participating in Upcoming Investor Conferences
June 1, 2026
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
May 21, 2026
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
May 14, 2026
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
May 7, 2026
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
April 7, 2026
Cognition Therapeutics CEO Issues Letter to Shareholders
March 31, 2026
1
2
Next Page
→